Abstract
Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.
Current Pharmaceutical Design
Title:Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue
Volume: 20 Issue: 42
Author(s): Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu
Affiliation:
Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.
Abstract: Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Export Options
About this article
Cite this article as:
Cavalcante Ludimila, Kelsen P. David and Yu H. Kenneth, Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140826154724
DOI https://dx.doi.org/10.2174/1381612820666140826154724 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy NF-κB Signature on the Aging Wall
Current Drug Metabolism Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery STAT Signaling and Cell Function
Current Genomics Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry Structural and Functional Organization of miRNAs
Current Pharmacogenomics Targeting Signalling Cross-Talk between Cancer Cells and Cancer-Associated Fibroblast through Monocarboxylate Transporters in Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Development, Validation, and Applications of Anisotropic Polarizable Molecular Mechanics to Study Ligand and Drug-Receptor Interactions
Current Pharmaceutical Design Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry